NCT04394845View on ClinicalTrials.gov

A Study of the Biodistribution and Safety of [18F]GTP1 in Healthy Japanese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 11, 2020

Primary Completion Date

October 9, 2020

Study Completion Date

October 9, 2020

Conditions
Alzheimer Disease
Interventions
DIAGNOSTIC_TEST

[18F]GTP1

\[18F\]GTP1 IV bolus injection of up to 370 megabecquerel (MBq) (10 millicurie \[mCi\]), with a maximum drug mass dose of 10 microgram (μg).

Trial Locations (1)

06510

Invicro, a Konica Minolta company, New Haven

Sponsors

Lead Sponsor

Genentech, Inc.

Collaborators (1)

Invicro
All Listed Sponsors
collaborator

Invicro

OTHER

lead

Genentech, Inc.

INDUSTRY

NCT04394845 - A Study of the Biodistribution and Safety of [18F]GTP1 in Healthy Japanese Participants | Biotech Hunter | Biotech Hunter